Mountain Group Capital

Mountain Group News

Latest News

G1 Therapeutics Announces Pricing of Initial Public Offering

RESEARCH TRIANGLE PARK, N.C., May 16, 2017 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage oncology company, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $105,000,000. In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of its common stock at…

NeuroTronik Announces $23.1 Million Series B Preferred Stock Financing

Funding to advance NeuroTronik CANS Therapy™ to improve the treatment of Acute Heart Failure in the Hospital Pre-clinical and clinical experience has been highly-encouraging as to the promise of the therapy

Dublin, Ireland and Durham, North Carolina, USA – 18 April 2017 – NeuroTronik Limited and NeuroTronik, Inc. today announced closing on a $23.1 million Series B Preferred Stock Financing, tranched in line with project plan milestones. The funding was led by Boston Scientific Group, plc. Other major investors include Hatteras Venture Partners, Synergy Life Science Partners, Lord Baltimore Investment Partners, Mountain Group Capital, and Sovereign’s Capital. The investor group also…

G1 Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

RESEARCH TRIANGLE PARK, NC – March 29, 2017 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that it will present preclinical data on trilaciclib, G1T38, and G1T48 at the 2017 American Association for Cancer Research (AACR) Annual Meeting, to be held April 1-5 in Washington, DC. Details on the two poster presentations are as follows: Title: Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and…

Blue Cross Blue Shield Association Evidence Street Issues Positive Assessment of Castle Biosciences’ Uveal Melanoma Gene Expression Test

G1 Therapeutics Initiates Three Drug Development Programs in Breast Cancer

Phase 2 trial of trilaciclib in triple-negative breast cancer Phase 1b/2a trial of G1T38 in estrogen receptor-positive breast cancer Oral SERD (G1T48) in IND-enabling studies; Phase 1 trial planned for 4Q17 RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2017 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage oncology company, announced today the expansion of its pipeline of novel cancer therapies with the initiation of three development programs in breast cancer. G1…

G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer

Phase 2 study evaluating potential of Genentech’s Tecentriq plus trilaciclib and chemotherapy as a first-line treatment for small-cell lung cancer patients expected to begin in first half of 2017

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. a clinical-stage oncology company, announced today a clinical trial collaboration with Genentech, a member of the Roche Group. A Phase 2 clinical trial is expected to begin in the first half of 2017 and will evaluate the combination of Genentech’s immune checkpoint, anti-PD-L1 antibody Tecentriq® (atezolizumab) with G1’s CDK4/6 inhibitor trilaciclib (G1T28) as a first-line treatment for…

AgTech Accelerator Corporation Announces the Addition of Animal Health Pioneer Elanco to Blue-Chip Investor Syndicate; Completes $20 Million First Closing

High Demand Enables AgTech Accelerator to Cultivate High-Value, Early-Stage, Commercially Viable Agricultural Technologies

RESEARCH TRIANGLE PARK, N.C. – November 2, 2016 – AgTech Accelerator™, a unique startup accelerator vehicle focused on discovering and developing emerging agricultural technology companies, today announced the closing of an additional $8.5 million in financing, nearly doubling its capital since the initial launch in May 2016. The additional financing brings its total capital commitments to $20 million. Elanco, a leader in developing products and knowledge services to improve animal…

NuSirt Biopharma and OWL Metabolomics Partner to Advance Treatment of NASH / Non-alcoholic Steatohepatitis

NuSirt Biopharma, a company dedicated to improving the lives of those with chronic metabolic diseases, and One Way Liver S.L. (OWL Metabolomics), a leader in the field of metabolomics and liver diseases diagnostics, today announced they have initiated a strategic partnership to develop novel diagnostic tools for ongoing drug evaluation trials for NuSirt’s fatty liver drug research candidate, NS-0200. Through their research collaboration, NuSirt and OWL will evaluate drug-induced lipidomic…

Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering

ALPHARETTA, Ga., June 01, 2016 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of $7.00 per share.  In addition, Clearside has granted the underwriters a 30-day option to purchase up to an additional 1,080,000…

G1 Therapeutics Secures $47 Million Series C Financing

Proceeds will advance lead CDK4/6 inhibitors through early and mid-stage clinical trials, expand pipeline in multiple oncology indications

RESEARCH TRIANGLE PARK, N.C., May 11, 2016 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage oncology company, announced today the completion of a $47 million Series C financing led by new investor Cormorant Asset Management. Additional new investors include Aju IB Investment, Cowen Private Investments, Franklin Templeton Investments and Rock Springs Capital. All existing investors participated in the financing: Eshelman Ventures, Hatteras Venture Partners, Lumira Capital, MedImmune Ventures, Mountain Group…

Next Page →